Freshness note: This analysis was last updated 26 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.
“President Trump said Americans are now paying or will pay 'the lowest price anywhere in the world for drugs' thanks to administration negotiations with pharmaceutical companies”
Summary
President Trump claimed Americans are paying or will pay the lowest drug prices in the world due to his administration's negotiations with pharmaceutical companies. According to fact-checking analysis, while the administration announced agreements with pharmaceutical companies, the claim about achieving the lowest prices anywhere in the world lacks substantiation and overstates the scope and impact of these negotiations.
Primary Sources
FactCheck.org rated Trump's claim as misleading, finding that while pharmaceutical negotiations occurred, the claim about achieving the lowest drug prices in the world is not supported by evidence
Evidence Supporting the Claim
- The Trump administration announced negotiations and agreements with pharmaceutical companies regarding drug pricing
- Some pharmaceutical companies made commitments regarding drug pricing during the administration
Evidence Against / Context
- The claim that Americans are paying or will pay the lowest drug prices anywhere in the world is not substantiated by available evidence, according to FactCheck.org
- The scope and impact of the pharmaceutical company negotiations were overstated in the claim
- Americans historically pay higher prescription drug prices compared to citizens in many other developed countries
Timeline
President Trump made public statements claiming Americans would have the lowest drug prices in the world due to administration negotiations
FactCheck.org published analysis rating the claim as misleading
What This Means
Structured interpretation — not opinion
Key takeaway 1
While the administration engaged in negotiations with pharmaceutical companies, the specific claim about achieving the lowest drug prices globally is not supported by current evidence
Key takeaway 2
Drug pricing comparisons require examining actual price data across countries, implementation timelines, and the scope of products covered by any agreements
Key takeaway 3
The characterization of pricing outcomes appears to exceed what the announced agreements are expected to deliver based on available fact-checking analysis
Related Claims in health
“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.